North China Pharmaceutical Company.Ltd600812.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, North China Pharmaceutical Company.Ltd (600812.SH) trades at a P/E of 87.00x, P/B of 1.95x, P/S of 1.27x, and a dividend yield of 0.56%.
Longitudinal percentile comparison: P/E sits at the 38th percentile over the trailing 10Y window (vs. 66th percentile over 3Y); P/B sits at the 64th percentile over the trailing 10Y window (vs. 88th percentile over 3Y); P/S sits at the 76th percentile over the trailing 10Y window (vs. 100th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 78th percentile within its industry and the 77th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.56%, ranking at the 82nd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 26.9 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. North China Pharmaceutical Company.Ltd operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600812 · SSE: 600812 · 600812
Want the full picture on whether North China Pharmaceutical Company.Ltd (600812.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 87.00 | ||||||
| P/B (MRQ) | 1.95 | ||||||
| P/S (TTM) | 1.27 | ||||||
| Dividend Yield | 0.56% | ||||||
| Buyback + Div Yield | 0.56% |